EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: risk of heart failure

Rosa Oh, Gyuri Kim, Kyu-Na Lee, So Hyun Cho, Ji Yoon Kim, Seohyun Kim, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Kyungdo Han, Jae Hyeon Kim

Cardiovascular Diabetology · 2024

DOI: 10.1186/s12933-024-02489-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Diabetology, 2024. Verfasst von Rosa Oh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Heart Failure. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: The association between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM) is unclear. This study aimed to investigate the impact of spectrum of SLD on the risk of heart failure and cardiovascular (CV) mortality in patients with T2DM. METHODS: In a nationwide cohort study, 2,745,689 adults with T2DM were followed from 2009 to 2012 until 2018. Participants were categorized into no steatotic liver disease (no SLD) and SLD groups. The SLD group was stratified based on metabolic risk factors, alcohol consumption and viral hepatitis. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for heart failure (HF) and CV mortality risk. RESULTS: The prevalence of MASLD, metabolic alcohol-associated liver disease (MetALD), alcohol-associated liver disease with metabolic dysfunction (ALD with MD) and MASLD with viral hepatitis (VH) was 49.6%, 7.2%, 2.3%, and 2.0%. Individuals with MASLD (adjusted HR [aHR], 1.11), MetALD (aHR, 1.14), ALD with MD (aHR, 1.32) and MASLD with VH (aHR, 1.12) had a higher risk of developing HF compared with the no SLD group. The risk of CV mortality was also increased in those with SLD groups compared to those with no SLD. The risk of new-onset HF and CV mortality showed a J-shaped association with alcohol consumption regardless of SLD status. CONCLUSION: SLD is independent risk factor of new-onset HF and CV mortality in persons with T2DM, and alcohol consumption has a J-shaped association with risk of HF and CV mortality, regardless of SLD status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Heart FailureHumansMaleFemaleMiddle AgedRisk AssessmentAgedPrevalenceTime FactorsPrognosisRisk FactorsAdultLiver Diseases, AlcoholicTaiwanHepatitis, Viral, HumanAlcohol DrinkingNon-alcoholic Fatty Liver DiseaseDatabases, Factual

Stichwörter der Autor:innen

Cardiovascular mortalityHeart failureSteatotic liver diseaseType 2 diabetes

Autor:innen und Institutionen

  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.
  • Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea.
  • Department of Statistics and Actuarial Science, Soongsil University, 369, Sangdo-ro, Dongjak-gu, Seoul, 06978, Republic of Korea. hkd917@naver.com.
  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. jaehyeonmd.kim@samsung.com.

Zitieren

APA

Oh, R., Kim, G., Lee, K. N., Cho, S. H., Kim, J. Y., Kim, S., Lee, Y. B., Jin, S. M., Hur, K. Y., Han, K., & Kim, J. H. (2024). Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: risk of heart failure. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-024-02489-4

Vancouver

Oh R, Kim G, Lee KN, Cho SH, Kim JY, Kim S, et al. Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: risk of heart failure. Cardiovascular Diabetology. 2024. doi:10.1186/s12933-024-02489-4

BibTeX
@article{Oh2024,
  author = {Oh, Rosa and Kim, Gyuri and Lee, Kyu-Na and Cho, So Hyun and Kim, Ji Yoon and Kim, Seohyun and Lee, You-Bin and Jin, Sang-Man and Hur, Kyu Yeon and Han, Kyungdo and Kim, Jae Hyeon},
  title = {Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: risk of heart failure},
  journal = {Cardiovascular Diabetology},
  year = {2024},
  doi = {10.1186/s12933-024-02489-4}
}
Kostenlos starten →